Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,694 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing. North America hit an all-time high of $250 million (+13% YoY), supported by Lanreotide generic launch and Albuterol market share gains to 17%. India branded prescription grew 10% YoY, while trade generic transition was completed, impacting near-term growth. PAT stood at INR 1,178 crore (17.6% of sales). Management guided EBITDA margin of 24.5%-25.5% for FY25 and expects U.S. sustainable run rate of $235-240 million. Key risks include Goa facility FDA classification (six 483 observations) and potential price erosion in Albuterol with new entrants.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.
- Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.
- Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.
- ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
Risks flagged
- Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
- New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
- Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
- Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains.
Key quotes
- North America reached all-time high quarterly revenue of $250 million.
- Our EBITDA for the year is trending in the range of 24.5%-25.5% and ROIC is well over 30%.
- The ANDA launch should hopefully add to this overall share. I think the ANDA also looks like any other product has a time to ramp up.
Research modules